Previous studies demonstrated that the MNK–eIF4E axis supported tumor metastasis and immune suppression, and MNK inhibition impaired protumor phenotype switching and potentiated antitumor immune responses in melanoma and breast cancer [35, 36]. This evidence concerns the gene EIF4E and breast cancer.